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Abstract
Objective: Treatment of acute lymphoblastic leukemia (ALL) in adults focuses on the initial assess-
ment of the prognostic relevant cytogenetic features as well as a response-guided therapy based on 
molecular data. We examined the importance of molecular-cytogenetic abnormalities for complete 
remission (CR) rates and the overall survival (OS) in adult ALLs.
Materials and Methods: Conventional cytogenetics and fluorescence in situ hybridization were per-
formed on bone marrow cells from 33 newly-diagnosed ALL adults. Two karyotype categories [stan-
dard-  risk  group-  normal  karyotype,  hyperdiplody  and  other  structural  aberrations,  and  high-risk 
group-t(11q23)/MLL, t(9;22)/bcr-abl, t(1;19), t(8;14), C-MYC and complex karyotype] and the bio-
logically and clinically relevant ALL ploidy subgroups were prospectively defined.
Results: Chromosomal abnormalities were found in 52% of the cases with a high rate of poor-risk trans-
locations - t(9;22), t(8q24), t(11q23), t(1;19). The total CR rate was 67% and the median time for achieve-
ment 2.33 months. Male sex, an age below 35 years and the absence of high risk translocations might have 
contributed to the high CR rates. Female patients, hyperdiplody, low white blood cells (WBC), and ran-
dom cytogenetic aberrations had the longest OS. OS, 3- and 5-years survival periods were significantly 
shorter for poor-risk than standard risk group (p=.015, p=.001 and p=.005, respectively).
Conclusion: This study emphasizes the lack of influence of cytogenetic aberrations on the CR and the 
time to achieve CR. However, our observations show that these aberrations are an independent prog-
nostic factor in adult ALL - they allow predicting therapy resistance and the OS time after intense
treatment. (Turk J Hematol 2011; 28: 176-85)
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Acute  lymphoblastic  leukemia  (ALL)  is  a  fairly 
uncommon disease in adults and is associated with 
a  poor  prognosis.  The  treatment  of  adult  ALL  is 
based on the initial assessment of relevant prognos-
tic  molecular-cytogenetic  features  and  response-
guided therapy based on molecular data. In more 
than 50% of adult ALL patients clonal chromosomal 
abnormalities that deregulate candidate oncogenes 
or transcription factors by introducing a heterolo-
gous  promoter  or  enhancer  are  observed  [1-3]. 
Altered cell cycle progression or upregulated tyro-
sine  kinase  activity  are  other  important  mecha-
nisms in ALL [2-5]. Most translocations can lead to 
generation of fusion genes that translate into chime-
ric oncogenic proteins, providing targets for novel 
therapeutic agents. The most important prognostic 
factors  in  ALL  are  cytogenetic  abnormalities,  the 
time to achieve complete remission (CR), the initial 
leukocyte  count,  age,  and  immunologic  subtype 
[4-8].  Cytogenetic  abnormalities  observed  in  ALL 
patients  are  among  the  most  important  indepen-
dent  prognostic  variables  that  predict  outcome; 
[5,6,9] ploidy and translocations are correlated with 
prognosis [10,11]
ALL  is  heterogeneous  and  can  be  subtyped 
based  on  chromosomal,  immunophenotypic,  and 
molecular  criteria.  The  prognostic  implications  of 
different ALL subtypes strongly influence the choice 
of treatment in adults [5,6,12]. Many patients with 
T-cell ALL can be cured with chemotherapy alone. 
In contrast, patients with early B-lineage ALL and 
certain chromosomal abnormalities, especially the 
Philadelphia  chromosome,  do  not  have  durable 
responses  to  chemotherapy  and  should  undergo 
bone marrow transplantation [13,14].
The aim of the present study was to determine 
the frequency and prognostic significance of molec-
ular-cytogenetic  abnormalities,  and  to  ascertain 
whether or not karyotype is a significant prognostic 
factor  in  adult  ALL  patients,  independent  of  new 
intensive chemotherapy regimens and initial clini-
cal characteristics.
Material and Methods
Study design
Patients
The study included 33 patients (aged >18 years) 
that were newly diagnosed with ALL at Alexandrovska 
University Hospital, Hematology Clinic, Sofia, Bulgaria 
during a 3-year period. Diagnosis of ALL was based 
on the French-American-British (FAB) classification 
system’s  morphological  and  cytochemical  criteria, 
and on lymphoid immunophenotype. 
Özet
Amaç: Erişkinlerde akut lenfoblastik lösemi (ALL) tedavisinde prognostik açıdan önemli sitogenetik 
özelliklerin değerlendirmesi ve bunun yanı sıra moleküler verilere göre yanıt yönlendirmeli tedaviye 
odaklanılmaktadır. Erişkin ALL’de tam yanıt (TR) oranları ve genel sağkalım (GS) için moleküler 
sitogenetik anomalilerin önemi incelenmiştir.
Yöntemler ve Gereçler: Yeni tanı alan 33 erişkin ALL’li hastadan alınan kemik iliği hücreleri klasik 
sitogenetik  ve  floresans  in  situ  hibridizasyon  yöntemi  ile  incelendi.  Olgular  iki  karyotip  grubuna 
[standart-risk grubu- normal karyotip, hiperdiplodi ve diğer yapısal aberasyonlar ve yüksek-risk grubu 
- t(11q23)/ MLL, t(9;22)/bcr-abl, t(1;19), t(8;14), C-MYC ve kompleks karyotip] ve biyolojik / klinik 
açıdan önemli ALL ploidi alt gruplarının ayrılarak tanımlanmıştır. 
Bulgular: Kötü riskli t(9;22), t(8q24), t(11q23), t(1;19) kromozom anomalileri yüksek orandadır,   
olguların %52’sinde belirlenmiştir. Toplam tam yanıt (TR) oranı %67 olup TR sağlanana kadar geçen 
ortalama  süre  2.33  aydır.  Erkek  cinsiyeti,  35’in  altındaki  yaş  ve  yüksek  risk  translokasyonlarının 
bulunmaması yüksek TR oranlarına ulaşılmasında katkıda bulunmuş olabilir. Kadın hastalar, hiperdip-
lodi, düşük lökosit sayısı (WBC) ve random sitogenetik anomaliler de en uzun GS gözlenmiştir. Üç ve 
beş yıllık sağkalım aralıklarında, GS, standart riskli gruba göre düşük riskli grupta anlamlı şekilde 
daha kısadır (sırasıyla p=.015, p=.001 ve p=.005).
Sonuç: Bu çalışmada sitogenetik aberasyonların TR oranı ve TR sağlanana kadar geçen süre üzerinde 
etkisinin bulunmadığı vurgulanmaktadır. Bununla birlikte gözlemlerimiz bu aberasyonların erişkin 
ALL’de bağımsız bir prognostik faktör olduğunu göstermektedir. Bu bulgular tedaviye direncin ve 
yoğun tedavi sonrası GS süresinin öngörülmesine izin verir. (Turk J Hematol 2011; 28: 176-85)
Anahtar kelimeler: Erişkin akut lenfoblastik lösemi, tam remisyon, karyotip, genel sağkalım
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Each  patient  underwent  a  standard  induction 
regimen  consisting  of  combination  anthracycline, 
vincristine,  prednisone,  and  cyclophosphamide, 
and prophylactic intrathecal methotrexate, methyl-
prednisolone,  and  cytarabine,  according  to  GET-
LALA-94  (Groupe  d‘Etude  et  de  Traitement  de  la 
Leucémie Aiguë Lymphoblastique de l’Adulte) [15]. 
CR was followed by multidrug consolidation treat-
ment,  central  nervous  system  prophylaxis,  late 
intensification, and maintenance chemotherapy for 
24 months. 
  
Definition of remission state
CR was defined as ≤5% blast cells in normocel-
lular  or  hypercellular  bone  marrow,  a  normal 
peripheral  and  differential  blood  count,  and  no 
extramedullary  disease.  Complete  remission time 
was defined as the time from diagnosis to CR.
Definition of resistant disease
ALL was considered as resistant disease (RD) if CR 
was not achieved after 3 courses of induction therapy.
Definition of overall survival
Overall survival (OS) was the time of treatment 
onset to the time of death. Patients were censored 
for survival only at the date they were last known to 
be in complete remission or alive, respectively.
Methods
Immunophenotyping
Immunophenotyping  was  performed  at 
Alexandrovska  University  Hospital,  Allergology  and 
Immunology  Clinic.  Leukemic  cells  obtained  from 
fresh bone marrow or peripheral blood samples col-
lected  in  EDTA-containing  tubes  were  analyzed. 
Surface,  cytoplasmic,  and  nuclear  antigens  were 
detected via a standard 2-color direct immunofluo-
rescence assay using a broad panel of commercially 
available  lymphoid  and  myeloid-associated  mono-
clonal antibodies (MoAbs).
According  to  the  European  Group  for 
Immunophenotyping  of  Leukemia  (EGIL)  [16], 
B-lineage acute leukemias were separated into the 
following 4 groups: pro-B-ALL (BI): CD19+, CD22+, 
cyCD79a+, CD10- cyIg-, and sIg-; common B-ALL 
(BII): CD10+ (CALLA+), cyIg-, sIg-; pre-B-ALL (BIII): 
CD10+/-, cyIg+, and sIg-; mature B-ALL (BIV): sIg+. 
T-lineage ALL was characterized based on CD1a, 
CD2,  CD3,  CD4,  CD5,  CD7,  and  CD8  cell  marker 
expression.  Myeloid  markers  (CD13,  CD33,  CD14, 
and CD15) were tested in most patients. For every 
antigen  tested  cell  expression  >20%  was  consid-
ered a positive reaction. 
Conventional cytogenetics
Conventional (routine) cytogenetic analysis was 
performed on material obtained from bone marrow 
aspiration.  Bone  marrow  was  treated  with  direct 
(without  cell  cultivation)  and  indirect  methods 
(after  48  h  of  cultivation  with  15%  fetal  bovine 
serum  at  37°C  in  RPMI)  to  obtain  metaphases. 
Chromosomes  were  stained  using  the  G-banding 
method  and  were  analyzed  via  light  microscopy 
and Icarus Metasystem software. Karyotypes were 
determined  according  to  International  System  for 
Human Cytogenetic (ISHC) nomenclature [17]. The 
presence of ≥2 metaphases with the same struc-
tural change, the same chromosome gain, or ≥3 
metaphases  with  deletion  of  the  same  chromo-
somes was considered as clonal aberration. At least 
20 metaphases for each patient were carried out. 
Hypodiploid  and  hyperdiploid  karyotypes  were 
defined  as  having  <45  and  >46  chromosomes, 
respectively.
Fluorescence in situ hybridization (FISH)
FISH analysis was performed on cytogenetic prep-
arations  obtained  from  bone  marrow  cells.  Direct 
labeling locus-specific probes (Vysis, Ltd.) were used 
for  MLL  gene  rearrangements,  bcr/abl  gene  fusion, 
and  C-MYC  rearrangements.  Fluorescence  signals 
were  detected  using  fluorescence  microscopy  and 
ISIS  Metasystem  software.  The  size  of  genetically 
abnormal clones was determined after analyzing at 
least 100 successfully hybridized cells. 
Statistical methods
The statistical variables tested for potential prog-
nostic value were as follows: molecular-cytogenetic 
abnormalities, age, WBC count, hemoglobin value, 
platelet  (PLT)  count,  immunologic  subgroup,  CR 
rates, frequency of RD, early deaths, and survival 
times. Three- and 5-year survivals were estimated 
using  the  life  tables’  method.  Kaplan-Meier  [18] 
curves were constructed for CR time and survival; A 
Log rank test was used to compare these curves in 
both cytogenetic groups.
Comparison  of  quantitative  variables  between 
patient groups was performed using one-way analy-
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performed using the chi-square test and t-test. All 
statistical  analyses  were  2-sided.  P  values  <0.05 
were considered statistically significant. 
Cytogenetic abnormalities were classified into 2 
groups,  as  follows:  1)  high  risk:  t(11q23)/MLL, 
t(9;22)/bcr-abl, hypodiploidy (<45 chromosomes), 
t(1;19), t(8q24)/C-MYC, and complex karyotype; 2) 
standard risk: normal karyotype, hyperdiploidy, and 
other structural aberrations. The parameters were 
selected according to internationally accepted prog-
nostic factors in ALL [7,11,19-21]. As a prognostic 
factor, cytogenetics was considered a binomial vari-
able (high-risk group versus standard-risk group).
Results
Clinical and biological characteristics of the patients
Clinical  and  biological  characteristics  of  the 
patients are shown in Table 1. The frequency of ALL 
increased with age; 61% of the patients were aged 
>35 years. More patients had B-cell leukemia (84.8%) 
than T-cell leukemia (15.2%, p<0.001), and most had 
a WBC count <30.109 /L (82%, p<0.001).
Cytogenetic data and correlations with clinical 
and hematological features
Based on routine cytogenetic and FISH analysis, 
clonal chromosomal abnormalities were noted in 17 
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Table 1. Clinical and biological features of the adult patients with newly diagnosed ALL
Characteristics  Parameters  n (%)  CR n (%)  Time to CR  OS
        (months)  (months)
Sex           
   Male   19 (57.6%)  14 (73.7%)  2.33 (0.97-3.69)  11.13 (8.05-14.21)
   Female   14 (42.4%)  8 (57.1%)  1.93 (1.05-2.81)  12.43 (4.80-20.06)
Age (years)           
   Median (range)   41 (18-74)     
   <35   13 (39%)  11 (84.6%)  1.43 (0.85-2.00)  10.16 (0.00-28.05)
   >35   20 (61%)  11 (55%)  0.60 (1.44-3.82)  12.33 (10.17-14.48)
WBC (×109 /L)           
   Median (range)   16.5 (1.7-300)     
   <30   27 (82%)  18 (66.7%)  2.40 (0.30-1.80)  12.43 (9.14-15.72)
   >30   6 (18%)  4 (66.7%)  1.36 (1.06-1.67)  6.66 (0.00-13.66)
Immunophenotype           
   B-lineage   24 (72.7%)  15 (62.5%)  2.33 (0.32-1.69)  8.50 (2.69-14.30)
   T-lineage*  5 (15.2%)  4 (80%)  2.33 (0.76-0.83) 
   Burkitt´s type-B lineage   4 (12.1%)  3 (75%)  1.36 (0.29-0.78)  10.86 (0.00-27.03)
Chromosomal pattern           
   Cell ploidy abnormalities         
   Normal diploid    16 (48.5%)  9 (56.3%)  1.93 (0.80-3.05)  12.43 (0.00-28.24)
   Pseudodiploid (46, abnormal)    13 (49.4%)  6 (46.2%)  1.40 (0.32-2.47)  10.16 (3.73-16.59)
   Hyperdiploid >46    4 (12.1%)  2 (50%)  2.50 (1.70-3.29)  17.36 (0.00-44.38)
   Hypodiploid    0 (0%)  0 (0%)   
   Structural abnormalities        
   Non-random    12 (36.3%)  6 (50%)  1.96 (0.92-3.01)  10.16 (3.89-16.43)
   Random    5 (15.2%)  3 (60%)  2.50 (0.45-4.54)  13.16 (0.00-30.41)
   Normal diploidy    16 (48.5%)  9 (56.3%)  1.93 (0.80-3.05)  12.43 (0.00-28.24)
*OS in T-lineage ALL was not estimated because more than 50% of the patients died. Median OS is the time, which are gone through 50% of patients in the respec-
tively group, CR- complete remission; OS- overall survivalof the 33 ALL patients (52%). Ploidy groups and struc-
tural  changes  were  analyzed  (Table  1).  The  ALL 
patients  were  divided  into  2  risk  groups  (Table  2) 
according to molecular-cytogenetic aberrations, and 
basic  biological  and  laboratory  parameters  at  the 
time of diagnosis: high risk (n=14, 42.4%) and stan-
dard risk (n=24, 69.7%). 
Cell ploidy abnormalities 
Distribution of chromosomal ploidy anomalies in 
the patients was as follows: normal (46, normal): 16 
cases (45.5%); hyperdiploidy (>46): 4 cases (12.1%); 
pseudodiploidy (46, abnormal): 13 cases (49.4%); 
hypodiploidy 0 cases (Table 1). Among the pseudo-
diploid karyotypes, changes were variable. The fol-
lowing chromosomes were involved with high fre-
quency in balanced translocations: 4, 7, 8, 9, 11, 14, 
and 22. The short arms of chromosomes 4 and 12 
were  involved  in  deletion  events.  In  3  patients 
hyperdiploidy (>46) was combined with structural 
aberrations t(9;22), del 12p, and del l4p. The inci-
dence of hyperdiploid cell lines in individual patients 
ranged  between  20%  and  100%  of  the  analyzed 
metaphases; chromosomes 8, 6, 12, and 21 were 
the most frequently involved.
Structural abnormalities
Structural changes were observed in 17 patients 
(52%) with high-risk translocations t(9;22)(q34;q11), 
t(8q24),  t(11q23),  and  t(1;19)(q23;p13).  The  other 
structural  abnormalities  exhibited  deletion  of  the 
short arm of chromosomes 4 and 12, and isochro-
mosome 7. 
Differences in CR rates
The  CR  rate  for  the  33  patients  was  67%;  11 
patients  did  not  achieve  CR.  The  median  time  to 
achieve  CR  was  2.33  months  (range:  1.47-3.19 
months).  Male  gender,  T-marker  expression,  age 
<35 years, and absence of high-risk translocations 
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Table 3. First CR and survival rates
Group  CR rates     Time to achieve CR (months)  RD rates or      OS rates
  (%)  Median  95% CI  Sign.  early death in   Median   95% CI  Sign.  3-year  5-year
          the first 3 months  (months)      survival  survival
High risk (n=14)  9 (41%)  1.97  1.30-3.36  0.515  6 (43%)  9.85  3.89-16.43  .015  10%  10%
Standard risk (n=24)  13 (59%)  2.33  0.92-3.01    8 (33%)  18.00  1.11-25.23    29%  24%
Total (n=33)  22 (100%)  2.33  1.47- 3.19    14 (42%)  13.93  9.27-15.39    19.5%  17%
CR- complete remission; CI- confidential interval; RD- resistant disease; OS- overall survival
Table 2. Pretreatment characteristics according to cytogenetic risk group
Group  Total  Age (years)*  WBC count   Hb (g/L)*  PLT count        Phenotype
      (×109 /L)*    (×109 /L)*  B-ALL  T-ALL
Poor risk**  14 (42.4%)  43.5 (25-63)  22.05 (3.6-300)  92.0 (49-161)  61.0 (5-147)  14  0
t(9;22)/bcr-abl  5  41.8 (33-58)  9.2 (3.6-20.1)  106 (87-161)  48 (5-125)  4  0
t(11q23)/MLL  2  25 (25-25)  184.0 (68-300.0)  95.5 (68-123)  76.5 (23-130)  2  0
t(8q24)/C-MYC  4  48.5 (25-63)  21.4 (7.7-33.6)  84 (67-106)  93.7 (8-147)  4  0
t(1;19)/E2A-PBX1  1  31  69.6  49  10  1  0
Complex karyotype  2  44 (33-55)  16.1 (3.6-28.6)  75 (63-87)  67.5 (10-125)  2  0
Standard risk**  24 (69.7%)  41.0 (18-72)  12.95 (1.7-300)  86.5 (58-149)  89 (7-214)  20  5
Normal karyotype  16  41.7 (18-72)  12.5 (1.7-87.3)  84.5 (58-149)  119.2 (17-214)  11  5
Hyperdiploidy  4  37.8 (31-49)  13.2 (3.6-23.0)  92 (86-136)  49.0 (7-125)  4  0
del (4p)  2  52 (49-55)  24.7 (20.7-28.6)  72 (63-82)  9 (8-10)  2  0
i(7q)  2  37.5 (25-50)  153.4 (6.8-300)  96.5 (68-125)  20 (17-23)  2  0
del(12p)  1  49  23.0  81  8  1  0
*Median and range in parentheses
WBC: White blood cells; Hb: hemoglobin; PLT: platelets
**Three patients had karyotypes with both high-risk and standard-risk abnormalities, and were included in both groupsmight have contributed to the high CR rate (Table 1). 
The CR rate was 64% in the high-risk group and 54% 
in  the  standard-risk  group  (p=0.755)  (Table  3). 
Patients  with  t(1;19),  i(7q),  and  del  (12p)  had  the 
highest CR rates (Table 4), but the number of patients 
with these aberrations was very low- 5 of 33 cases.
Female  gender,  age  >35  years,  Burkitt’s-type 
ALL, and pseudodiploidy were associated with the 
shortest time to first CR (Table 1). The median time 
to achieve CR was not statistically different between 
the 2 groups 2.3 months in the standard-risk group 
and  1.9  months  in  the  high-risk  group  (p=0.515) 
(Table 3). Patients with t(9;22)/bcr-abl had the lon-
gest time to CR and the highest RD rate (Table 4). 
Differences between 3-year, 5-year, and 
overall survival
Patients with hyperdiploidy karyotypes, a low WBC 
count, random cytogenetic aberrations, and females 
had the longest OS (Table 1). As indicated in Table 3 
and the Figure, median OS was significantly shorter in 
the high-risk group (9.85 months) than in the standard-
risk  group  (18  months)  (p=0.015).  The  estimated 
3-year survival was 19.5% for all patients; 10% for the 
high-risk  group  vs.  29%  for  the  standard  risk  group 
(p=0.001). In all, 17% of the patients had 5-year sur-
vival; 10% in the high-risk group and 24% in the stan-
dard risk group (p=0.005). A significant difference in 
OS was observed between the patients with and with-
out CR (p=0.001) (Table 5). 
A  comparison  of  the  frequency  and  types  of 
molecular-cytogenetic aberrations in the immuno-
logical subgroups is presented in Table 6. The fre-
quency of В-lineage ALL (28 cases, 84.8%) was sta-
tistically higher than T-lineage ALL (5 cases, 15.2%) 
(p<0.001). Among the B-ALL patients, 60.7% were 
common B-ALL (BII), 17.9% were pro-B ALL (BI), 
17.9%  were  mature  B-ALL  (B-IV),  and  3.5%  were 
pre-B ALL (B-III). 
Discussion
 
It has been reported that cytogenetics is the most 
important  prognostic  factor  in  adult  ALL  patients 
[12,22-25]. Based on their results, these researchers 
were able to classify patients into standard-, inter-
mediate-, and high-risk groups with significant dif-
ferences in survival. 
The present study compared patient characteris-
tics, molecular-cytogenetic data, CR, and OS in a 
group of 33 newly diagnosed adult ALL patients that 
were treated with the standard adult ALL protocol. 
In all, 42.4% of the patients were included in the 
high-risk  group.  All  the  patients  were  aged  >35 
years (except MLL (+) patients with a median age 
of 25 years, p=0.02). The median time to achieve 
CR differed insignificantly between the 2 molecular-
cytogenetic  groups.  Interestingly,  time  to  CR  was 
shorter in the high-risk group than in the standard-
risk group. 
The  Philadelphia  (Ph)  chromosome  was  the 
most frequent karyotypic aberration in the high-risk 
group (35.7% in the high-risk group versus 15.15% in 
all 33 ALL patients), which is higher than previously 
reported (15%- 30%) [7,13,19,26-30]. Our observa-
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Table 5. OS (months) according to remission status
Status remission   Number  Percents      OS (months)
      Median   Std. Error    95% CI
Patients without CR  11  33.3%  4.33  1.96  0.49  8.18
Patients with CR  22  66.7%  13.17  8.06  0.00  28.96
Overall  33  100%  12.33  1.56  9.27  15.39
OS- Overall survival, CI- confidential interval
Table 4. Estimated CR rates, and time to first CR or RD accord-
ing to molecular-cytogenetic abnormalities
Groups  Cytogenetic   CR rates  Time to  RD rate or
  aberrations  (%)  achieve  early death
      CR   in the first 
      (months)  3 months
High risk   t(9;22)/bcr-abl  60%  2.73  60%
(n=14)  t(11q23)/MLL  50%  1.0  50%
  t(8q24)/C-MYC  75%  1.9  50%
  t(1;19)/E2A-PBX1  100%  1.4  0%
  complex karyotype  50%  2.5  50%
Standard   normal karyotype  60%  1.7  40%
risk (n=24)  hyperdiploidy  50%  2.25  50%
  del (4p)  50%  2.57  50%
  i (7q)  100%  1  0%
  del(12p)  100%  2.5  0%
CR- complete remission; RD- resistant diseasetion  pointed  for  variable  immunophenotypes  in 
Ph(+) ALL, without any apparent connection to a 
specific phenotype. Leukemic blasts in Ph(+) ALL 
expressed B-lineage-specific markers and aberrant 
myeloid markers in 3 of the 4 cases. According to 
Tabernero et al., [31] the frequency of myeloid co-
expression in Ph(+) ALL is higher than that in Ph(-) 
ALL. High myeloid expression of CD13, CD33, and 
CD15 in 75% of lymphoblasts in Ph(-) ALL has been 
observed. In the present study patients with t(9;22) 
and/or bcr/abl rearrangements had a 60% CR rate 
and  longer  time  to  CR  (2.73  months)  than  other 
cases in the high-risk group. 
In all, 14.3% of the high-risk patients and 6.1% of 
all  the  patients  in  the  present  study  had  t(4;  11)
(q21;q23)  translocation  and/or  rearrangement  of 
the MLL gene. Most leukemic blasts with this trans-
location had a pro-B-ALL or CALLA(+) phenotype. 
One  MLL(+)  patient  expressed  myeloid  antigens 
CD33 and cyCD13 without fulfilling the criteria for 
biphenotypic  leukemia.  The  lowest  median  age 
was in patients with 11q23/MLL and a high correla-
tion index (r=0.999) of the translocation with a high 
leukocyte level (median WBC count: 95.5×109/L). 
CR was achieved in 1 of the MLL cases. The time to 
CR was the shortest (1 month), despite the pres-
ence of markers of poor prognosis (high WBC count 
and  myeloid  co-expression).  These  findings  high-
light  the  difficulty  in  confirming  the  independent 
prognostic  importance  of  relatively  small  cytoge-
netic  subgroups  that  are  strongly  correlated  with 
other risk factors, such as the WBC count and age 
[20,23,32-34]. In the present study the frequency of 
8q24  translocations  and/or  rearrangements  of  the 
C-MYC proto-oncogene was high 28.6% in the high-
risk group and 12% in all 33 patients. Translocations 
(8q24)/C-MYC are the molecular-cytogenetic label 
of  Burkitt’s  leukemia/lymphoma  [7,21,22,34,35]. 
Interestingly, only 3 of the 33 patients in the present 
study had typical mature B-cell phenotype-positive 
CD19, CD20, CD10, surface IgM, and CD 79a, and 
negative CD5, CD23, and TdT. Among the pre-B-ALL 
patients,  involvement  of  the  MYC  gene  was  con-
firmed in 1. This is not the first time that t(8;14) has 
been reported beyond the context of mature B-ALL 
[36]. The presence of t(8q24)/C-MYC is associated 
with poor prognosis and a low CR rate [7,23,33,35,37]. 
We observed a high CR rate (75%) in the present 
study, but 50% of 8q24 cases had RD or early death 
in the 3 months following diagnosis. 
Translocation t(1;19)(q23;p13) was observed in 1 
(2.9%) of the ALL patients in the present study; the 
patient had a high WBC count (69.6×109/L), very 
low  hemoglobin  (49g/L),  and  low  PLT  count 
(10x109/L). This translocation is a rare cytogenetic 
aberration in adult ALL and correlates with imma-
ture  B-lineage  phenotypes,  especially  pro-B-ALL 
[7,32,37,38]. The patient’s leukemic blasts present-
ed as non-typical for t(1;19) more mature immuno-
phenotype with expression of CD10 (CALLA ) anti-
gens.  CR  in  this  t(1;19)(+)  patient  was  achieved 
rapidly  and  without  therapy  resistance  1  month 
after starting the initial treatment.
Complex chromosomal abnormalities are rare in 
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Table 6. Cytogenetic and laboratory data according to phenotype
  Pro   Common  Pre  Mature  T-ALL
  B-ALL  B-ALL  B-ALL  B-ALL 
Total patients  5  17  2  4  5
Normal karyotype  3  8  0  1  5
Hyperdiploidy  2  1  1  0  0
Translocations  1  5  2  3  0
Deletions  1  4  0  0  0
Complex karyotype  0  1  1  0  0
Age* (years)  44.6  40.7  27.5  49  36.8
WBC* (×109/L)  20.7  67.5  13.8  36.8  24.0
Hb* (g/L)  80.4  88.0  96.5  74.6  83.4
PLT* (×109/L)  66.8  79.5  66.5  67.5  112
CR rate (%)  40%  64.70%  100%  75%  80%
Figure 1. Estimated OS (months) according to cytogenetic risk 
group. Standard-risk group: normal karyotype, hyperdiploidy, and 
other structural aberrations; high-risk group: t(11q23), t(9;22), 
t(1;19), t(8;14), and complex karyotypeadult ALL patients [7,8,10,12,39]. Using cytogenetic 
methods we characterized complex karyotypes in 2 
of the 33 cases (6.1%); among them, only 1 achieved 
hematological CR, despite the presence of Ph(+) 
blasts in multiple chromosomal aberrations. Among 
the 33 patients in the present study, 24 (73%) were 
in the standard-risk group, which had the highest 
prevalence of normal karyotypes (62.5%). This fre-
quency  correlates  with  previously  published  data 
[12,22,24]. Patients in the standard-risk group had a 
higher  rate  of  first  CR  (59%  vs.  41%  in  high-risk 
group,  p=0.775),  but  the  time  to  CR  was  longer 
(2.33  vs.  1.9  months,  p=0.515).  The  standard-risk 
group had a lower RD and early death rates (33%) 
than the high-risk group (43%, p=0.05). Studies of 
survival  in  adult  ALL  patients  have  consistently 
shown  that  those  with  standard-risk  cytogenetic 
aberrations  survive  longer  than  do  patients  with 
poor prognostic abnormalities. In the present study 
median  OS  in  standard-risk  patients  was  signifi-
cantly longer (18 months vs. 9.85 months, p=0.02).
To date, analysis of cytogenetic aberration chang-
es in cell ploidy in adult ALL patients are rare, but 
are  most  often  combined  with  structural  abnor-
malities (pseudodiploid (46, abnormal). Most likely 
they have no clear self-diagnostic or prognostic sig-
nificance, as in pediatric ALL patients [10,11,35,40]. 
Poor  prognosis  associated  with  pseudodiploidy  is 
likely a reflection of structural rearrangements and 
other  unfavorable  features.  CR  was  achieved  in 
patients  with  the  hyperdiploidy  karyotype  only 
among those without t(9;22) or bcr/abl rearrange-
ments. 
Among the structural aberrations in adult ALL, 
deletions  and  isochromosomes  were  the  second 
most frequent changes after translocations [7,11,33]. 
These chromosome abnormalities are usually clas-
sified as miscellaneous or random changes with an 
unclear disease prognosis [12,22,23] Inactivation of 
tumor suppressor genes located in regions 4p, 12p, 
and 7q often leads to the start of a leukemic process 
[7,11,33,41]. In all but 1 of the patients in the present 
study  with  a  combination  of  del(4p)  and  t(4;11) 
deletions  presented  as  single  cytogenetic  aberra-
tions. Despite having unfavorable pretreatment lab-
oratory characteristics (age >35 years and low PLT 
count), the patients with miscellaneous abnormali-
ties had a better CR rate than the patients with non-
random chromosome changes. 
Distribution of immunophenotypes in the pres-
ent study was similar to that previously published 
[41-43].  Numerical  and  structural  translocations 
were more frequent in the mature B-ALL (75% of B 
IV cases) and pre-B-ALL (100%) patients. A lot of 
them  were  with  poor  prognostic  significance  - 
t(9;22)/bcr-abl, t(8q14)/C-MYC and complex karyo-
type. The high CR rate in these patients (100% in 
pre-B-ALL  and  75%  in  mature  B-ALL)  show  that 
molecular-cytogenetic  abnormalities  were  impor-
tant, but not determinative of the achievement of 
the first CR, and that pretreatment laboratory and 
biological characteristics affected the management 
of the disease. The most common lymphoblast leu-
kemia among the presented patients was common 
B-ALL (51.5%), which was associated with a high 
WBC  count  at  presentation  and  high-risk  cytoge-
netic aberrations. The common B-ALL patients had 
a higher incidence of Ph/bcr-abl(+) leukemia (24% 
of the common B-ALL cases) and a lower CR rate 
(64.7%) than the mature B-ALL patients. The pro-B-
ALL  (BI)  patients  had  the  lowest  CR  rate  (40%), 
despite  the  presence  of  standard-risk  cytogenetic 
changes. It is likely that the immunologically imma-
ture  features  of  leukemic  blasts  were  associated 
with poor disease outcome. 
In all, 25%-30% of adult ALL cases have T-lineage 
ALL [42,44-46]. We studied a small group of T-ALL 
patients  (15.2%  of  all  ALL  cases)  and  observed  a 
higher CR rate in the T-ALL patients than in the B-ALL 
and Burkitt’s-type leukemia patients. The CR rate in 
the  adult  ALL  patients  appeared  to  be  influenced 
positively by the absence of high-risk translocations 
and favorable pretreatment laboratory characteristics.
Conclusion
The present study shows that karyotype was an 
independent  prognostic  factor  in  the  adult  ALL 
patients for predicting OS following intensive treat-
ment  regimens,  and  that  laboratory  and  biologic 
features  (age,  and  WBC  and  PLT  counts),  and 
immunophenotype greatly influenced CR and dis-
ease outcome. 
This  small  cohort  of  adult  ALL  cases  and  the 
high-quality cytogenetic data obtained demonstrate 
the  value  of  cytogenetics  for  identifying  patients 
with high and low risk of treatment failure. Future 
randomized  clinical  trials  on  adult  ALL  can  and 
should use cytogenetic data to stratify patients into 
appropriate risk groups, so as to ensure they receive 
the most suitable therapy. 
Additional  cytogenetic  and  molecular  genetic 
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characterize  this  disease,  thereby  increasing  the 
number of patients than can benefit from alterna-
tive treatment strategies. 
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